Becton, Dickinson and Company

Becton, Dickinson and Company (BD) is a global medical technology leader headquartered in Franklin Lakes, New Jersey. Founded in 1897, the company has evolved from a manufacturer of glass syringes and thermometers into a massive, diversified medical technology enterprise. BD focuses on improving patient outcomes and clinical efficiency through a portfolio that spans medical delivery, interventional surgery, and connected care solutions. Following a major 2026 restructuring that spun off its biosciences and diagnostic divisions, the company has sharpened its focus on high-growth areas such as drug delivery systems for biologics and AI-driven patient monitoring. The company operates through four primary pillars: Medical Essentials, Connected Care, BioPharma Systems, and BD Interventional. By integrating hardware with digital platforms, BD provides critical infrastructure for hospitals and pharmacies, including medication management systems, infusion pumps, and advanced surgical instruments. With a long history of innovation—ranging from the invention of the Vacutainer to modern robotic pharmacy automation—BD remains a foundational player in the global healthcare supply chain, dedicated to advancing the world of health through transformative technology.

Advancing the world of health™.

• Pioneered the first mass-produced disposable needles and the Vacutainer blood collection system.
• Acquired CareFusion in 2015 and C.R. Bard in 2017 to significantly expand market reach.
• Completed a major strategic spin-off of its biosciences and diagnostic solutions business in 2026.
• Acquired Edwards Lifesciences’ Critical Care unit for $4.2 billion to enhance AI-driven monitoring capabilities.
• Recognized for long-standing contributions to global public health and medical infrastructure.

Sources

• BD Official Website
• BD Investor Relations